tirzepatide and nash Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review Tirzepatide achieves high NASH resolution

McGibbon, A., Adams, L., Ingersoll, K., Kader, T

In the context of GLP-1 therapy, glycine addresses the single biggest concern that clinicians and patients share: losing muscle along with fat

Thanh Hng gii thch, d l nhn hng dc m phm cn non tr x s Ph Tang, Sakura vi s mnh mang n sc p, sc kho v hnh phc cho mi ngi, c mt ti Vit Nam t 2014, Dc m phm Sakura c hng triu ph n Vit s dng v tin tng

10.1038/s41574-021-00489-y 113 PhaniendraA.BabuD

Unlike semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP), the additional glucagon receptor layer drives hepatic fat oxidation and increases resting energy expenditure through a mechanism that works independently of appetite suppression